Following on from information provided to NICE by the company in November 2011, the appraisal of Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 488
Referral date 01 November 2011
Topic area
  • Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 November 2022 Discontinued. Following on from information provided to NICE by the company in November 2011, the appraisal of Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
7 November 2011

As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of bevacizumab in combination with chemotherapy for the second line treatment of human epidermal growth factor 2 (HER2) negative metastatic breast cancer as part of our 27th work programme.

The Institute has now been informed by the manufacturer that it has decided not to apply for a centralised marketing authorisation for this indication. NICE has therefore decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual